[Clinical randomized comparative trial of ProMACE-CytaBOM regimen and CHOP regimen in treating non-Hodgkin's lymphoma].
OBJECTIVE
CHOP regimen is the routine modality for moderately or highly malignant non-Hodgkin's lymphoma (NHL). Previous reports show that ProMACE-CytaBOM regimen could elevate complete response rate and survival rate of patients with moderately or highly malignant NHL. This study was to compare efficacies and safeties of ProMACE-CytaBOM and CHOP regimens in treating this disease, to indicate the standard treatment for it.


METHODS
A total of 146 patients with moderately or highly malignant NHL, verified by pathology or histology, were randomized into trial group (73 patients treated with ProMACE-CytaBOM regimen) and control group (73 patients treated with CHOP regimen). Survival rate was analyzed by Kaplan-Meier method. Chi-square test was performed between groups.


RESULTS
The complete response rate, partial response rate, and response rate was significantly higher in ProMACE-CytaBOM group than in CHOP group (39.7% vs. 31.5%, 38.4% vs. 28.8%, and 78.1% vs. 60.3%, respectively, P < 0.05). The 1-, 3-, and 5-year survival rates were significantly higher in ProMACE-CytaBOM group than in CHOP group (89.3% vs. 82.1%, 76.2% vs. 51.4%, and 45.7% vs. 32.3%, respectively, P < 0.05). The major side effects, appeared with no differences (P > 0.05) in incidences between 2 groups, were leukopenia, thrombocytopenia, and nausea. Each group had 1 case of treatment-related death.


CONCLUSIONS
The results show higher efficacy of ProMACE-CytaBOM regimen over CHOP regimen. ProMACE-CytaBOM regimen may prolong survival time of patients with moderately or highly malignant NHL.
Hou
Mei
M
Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, P. R. China. houm118@msn.com
Li
Lu
L
Qiu
Meng
M
Yan
Xi
X
Zhu
Jiang
J
Gou
Hong-Feng
HF
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000401:mortality; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction; D015996:Survival Rate; D013921:Thrombocytopenia / Q000139:chemically induced; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D003561:Cytarabine; D001761:Bleomycin; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone; D008727:Methotrexate